Selected for oral presentation and two media highlight spots at AACR
TORONTO, Oct. 16 /CNW/ - ARIUS Research Inc., (TSX: ARI), a biotechnology
company discovering and developing the next wave of antibody therapeutics,
today announced that it has been selected to deliver a proffered paper in an
oral presentation on one of the six abstracts it will present at the
AACR-NCI-EORTC 2007 International Conference on Molecular Targets and Cancer
Therapeutics, held on October 22nd-26th in San Francisco. The Company will
deliver presentations that will disclose new findings related to its CD44,
TROP-2, CD59, CD9 and MCSP antibody programs. ARIUS scientists have also been
selected to discuss two of the Company's abstracts at the AACR press
"The inclusion of six ARIUS abstracts, two media highlight spots and one
oral presentation in this year's AACR-NCI-EORTC conference is an important
accomplishment for our Company, reflecting the high quality of our research
and the scientific community's interest in our programs," said Dr. David
Young, President and CEO. "We are especially proud that our Trop-2 Signal
Transduction Program abstract was one of only 12 selected from more than
900 abstracts for presentation as a proffered paper. Being chosen for an oral
presentation slot at this important conference is a highly-regarded
achievement and will attract greater attention to our cancer drug portfolio."
ARIUS scientists Dr. Amandine Truong, Ph.D. and Dr. Baldwin Mak, Ph.D.
will discuss the Company's findings for the following two abstracts at the
AACR press conference on Thursday, October 25th at 9:30 a.m. PT.
"AR47A6.4.2, a functional naked monoclonal antibody targeting Trop-2,
demonstrates in vivo efficacy in human pancreatic, colon, breast and prostate
cancer models." Proffered Paper Session 3, Thursday, October 25, 2007 from
5:15 - 5:30 p.m. in the Third Floor Ballroom at Moscone Center.
ARIUS' abstract and accompanying oral presentation examine the mechanism
of action of its Trop-2 targeting antibody. Trop-2 is a protein expressed on
the cell-surface and found in many cancer indications including pancreatic,
colon, breast and prostate cancer. The target is thought to be a key part of
the expansive MAPK pathway. The oral presentation will be delivered by Dr.
Amandine Truong, Ph.D., ARIUS Research Scientist.
"AR36A36.11.1, a monoclonal antibody targeting CD59, enhances complement
activity and exhibits potent in vivo efficacy in multiple human cancer
models." Session A, Tuesday, October 23, 2007, between 12:30-2:30 p.m. and
ARIUS' poster presentation discusses CD59, a widely expressed target in
malignant tumors that allows cancer cells to evade the immune system. ARIUS'
CD59 targeting antibody has the potential to help to activate the immune
system in addition to targeting cells directly. The target has been expressed
in a large number of cancer indications including breast, colon, lung and
Information regarding additional ARIUS abstracts:
"Chimeric and humanized versions of the anti-CD44 monoclonal antibody
ARH460-16-2 have potent anti-tumor efficacy in established models of human
breast and metastatic liver cancer." Session A, Tuesday, October 23, 2007,
between 12:30-2:30 p.m. and 5:30-7:30 p.m.
"Identification and characterization of an antibody to the CD9
tetraspanin: Therapeutic implications for cancer treatment." Session A,
Tuesday, October 23, 2007, between 12:30-2:30 p.m. and 5:30-7:30 p.m.
"A monoclonal antibody targeting melanoma-associated chondroitin sulfate
proteoglycan demonstrates antitumor activity in human melanoma, ovarian and
breast cancer models." Session B, Wednesday, October 24, 2007, between
12:30-2:30 p.m. and 5:30-7:30 p.m.
"Toxicology and pharmacokinetics of chimeric ARH460-16-2, a therapeutic
monoclonal antibody targeting CD44." Session B, Wednesday, October 24, 2007,
between 12:30-2:30 p.m. and 5:30-7:30 p.m.
ARIUS is a biotechnology company discovering and developing the next wave
of antibody therapeutics. Established in 1999, ARIUS has built a proprietary
technology platform, FunctionFIRST(TM), that rapidly identifies and selects
antibodies based on their functional ability to affect disease. This antibody
generation engine has enabled ARIUS to assemble a portfolio of more than 400
antibody candidates. In addition to the antibodies it is developing in-house,
ARIUS has ongoing partnerships with key biotechnology and drug development
companies. ARIUS is listed on the TSX under the symbol "ARI". For further
information, visit www.ariusresearch.com
Certain statements in this news release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements in this release include, but are not
limited to, ARIUS successfully advancing its new product programs as well as
licensing opportunities. These statements are only predictions and actual
events or results may differ materially. Factors that could cause such actual
events or results expressed or implied by such forward-looking statements to
differ materially from any future results expressed or implied by such
statements include, but are not limited to: early stage of development;
technology and product development; dependence on and management of current
and future corporate collaborations; future capital needs; uncertainty of
additional funding; no assurance of market acceptance; dependence on
proprietary technology and uncertainty of patent protection; intense
competition; manufacturing and market uncertainties; and government
regulation. These and other factors are described in detail in ARIUS' Annual
Report, forthcoming news releases and other filings with Canadian securities
regulatory authorities available at www.sedar.com. Forward-looking statements
are based on our current expectations and ARIUS is not obligated to update
such information to reflect later events or developments.
For further information:
For further information: Warren Whitehead, C.M.A., Chief Financial
Officer, ARIUS Research Inc., (416) 862-2323 ext. 214,
email@example.com, firstname.lastname@example.org; James Smith, Investor
Relations, (416) 815-0700 ext. 229, email@example.com